Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.47 |
| ▸ | CA9 | Q16790 | 3/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CCKAR | P32238 | 9/20 | 0.46 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | RXRA | P19793 | 1/20 | 0.41 |
| ▸ | RXRB | P28702 | 1/20 | 0.41 |
| ▸ | RXRG | P48443 | 1/20 | 0.41 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.41 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14562016 | 0.90 | PTGS2 (0.48) | PTGS2CA9CA1CA2CCKAR | |
| SCHEMBL14562019 | 0.90 | PTGS2 (0.48) | PTGS2CA9CA1CA2CCKAR | |
| SCHEMBL14562021 | 0.85 | CA9 (0.60) | PTGS2CA9CA1CA2CCKAR | |
| SCHEMBL860864 | 0.84 | PTGS2 (0.46) | PTGS2CA9CA1CA2CCKAR | |
| SCHEMBL861051 | 0.84 | RXRA (0.61) | PTGS2CA9CA1CA2CCKAR | |
| SCHEMBL14562025 | 0.83 | PTGS2 (0.60) | PTGS2CA9CA1CA2CCKAR | |
| SCHEMBL860872 | 0.82 | PTGS2 (0.53) | PTGS2CA9MALT1SMPD1PPP1CA | |
| SCHEMBL14562018 | 0.81 | PTGS2 (0.49) | PTGS2CA9CA1CA2CCKAR | |
| SCHEMBL14562005 | 0.81 | CA9 (0.72) | PTGS2CA9CA1CA2ALOX5 | |
| SCHEMBL861691 | 0.80 | SMN1; SMN2 (0.64) | CA9SMPD1PPP1CASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | TANABE SEIYAKU CO., LTD. (JP) | 2007-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060629-A1 | Large conductance calcium-activated k channel opener | KCNN3, KCNN1, KCNN2 | PTGS2 594/4885CA9 1406/4885CA1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.